Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (TSX:APS)

2.290 UNCHANGED
Streaming Delayed Price Updated: 10:20 AM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
Company to Hold Clinical Update Webcast; Details Forthcoming 
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Present at the Cantor Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — 
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Results for the Second Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Presents Highlights from Clinical Update
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Provides Update on Reverse Stock Split
Common Shares to begin trading on adjusted basis June 6 
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
EHA Abstract on Tuspetinib and Venetoclax Recently Published 
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Enters into $25 Million Committed Equity Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Results for the First Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Results for the Fourth Quarter and Full Year 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
Data to be presented in poster at ASH Annual Meeting 
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation 
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Results for the Third Quarter 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.